Halozyme Therapeutics | HALO - Cash And Equivalent

Stock Price
81.23
Daily Change
2.81 3.58%
Monthly
8.15%
Yearly
42.26%
Q1 Forecast
69.50

Halozyme Therapeutics reported $419.66M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amarin USD 122.8M 25.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Baxter International USD 1.73B 40M Sep/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
DBV Technologies USD 69.84M 33.37M Sep/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Halozyme Therapeutics USD 419.66M 357.8M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
MannKind USD 127.39M 70.39M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025